TSXV biotech
NurExone Targets H1 2027 IND Filing for ExoPTEN
NurExone Biologic Inc. (TSXV: NRX; OTCQB: NRXBF; FSE: J90) is targeting a potential investigational new drug submission for ExoPTEN during the first half of 2027 as it advances preclinical and manufacturing activities for the experimental therapy. The timeline was included in NurExone’s second-quarter update, released August 31. ExoPTEN is an exosome-based candidate being developed for…
Rakovina Raises C$1.99M for AI-Designed Cancer Programs
Rakovina Therapeutics Inc. (TSXV: RKV; FSE: 7JO0) has completed an upsized private placement that raised aggregate gross proceeds of C$1.991 million to support its preclinical cancer-drug pipeline. According to the August 31 financing announcement, the company issued 19.91 million units at C$0.10 each across two tranches. Each unit contained one common share and one-half warrant.…
Theralase Closes C$3.6M Financing for Ruvidar Development
Theralase Technologies Inc. (TSXV: TLT; OTCQB: TLTFF) has closed a brokered private placement that raised gross proceeds of C$3.555 million, providing additional capital for its cancer and antiviral development programs. According to the August 24 announcement, Theralase issued 14,812,500 units at C$0.24 per unit. Each unit contains one common share and one warrant exercisable at…
